{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:25:26Z","timestamp":1759937126967},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ejpb.2015.04.018","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T23:24:36Z","timestamp":1430609076000},"page":"346-352","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections"],"prefix":"10.1016","volume":"93","author":[{"given":"Manuela","family":"Carvalheiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Alexandra","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Santos-Mateus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui M.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Armanda","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla V.","family":"Eleut\u00e9rio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effie","family":"Scoulica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Santos-Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Eug\u00e9nia M.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.04.018_b0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10096-011-1276-0","article-title":"Leishmaniasis: new insights from an old and neglected disease","volume":"31","author":"Antinori","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejpb.2015.04.018_b0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/bmj.326.7385.377","article-title":"Leishmaniasis: new approaches to disease control","volume":"326","author":"Davies","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejpb.2015.04.018_b0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy-challenges and opportunities","volume":"17","author":"Croft","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejpb.2015.04.018_b0020","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"Croft","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejpb.2015.04.018_b0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/092986709787458489","article-title":"Leishmaniasis: current treatment and prospects for new drugs and vaccines","volume":"16","author":"Kedzierski","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.04.018_b0030","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.trstmh.2006.03.009","article-title":"Miltefosine \u2013 discovery of the antileishmanial activity of phospholipid derivatives","volume":"100","author":"Croft","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ejpb.2015.04.018_b0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","article-title":"Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use","volume":"9","author":"Perez-Victoria","year":"2006","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejpb.2015.04.018_b0040","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2015.04.018_b0045","doi-asserted-by":"crossref","unstructured":"M.E.M. Cruz, M.M. Gaspar, M.B. Martins, M.L. Corvo, Liposomal Superoxide Dismutases and Their Use in the Treatment of Experimental Arthritis. Duzgunes, N. Methods in Enzymology. [22], Amsterdam, Elsevier. Liposomes, Part E, 2005, 395\u2013413.","DOI":"10.1016\/S0076-6879(05)91022-7"},{"key":"10.1016\/j.ejpb.2015.04.018_b0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425240903548232","article-title":"Drug delivery strategies for therapy of visceral leishmaniasis","volume":"7","author":"Gupta","year":"2010","journal-title":"Expert Opin. Drug Delivery"},{"key":"10.1016\/j.ejpb.2015.04.018_b0055","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.75.6.2959","article-title":"Therapy of leishmaniasis \u2013 superior efficacies of liposome-encapsulated drugs","volume":"75","author":"Alving","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.04.018_b0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2015.04.018_b0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0304-4017(01)00389-2","article-title":"Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation","volume":"97","author":"Valladares","year":"2001","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.ejpb.2015.04.018_b0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.addr.2007.04.009","article-title":"Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles","volume":"59","author":"Date","year":"2007","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ejpb.2015.04.018_b0075","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1517\/17425247.2010.529897","article-title":"New delivery strategies for the old pentavalent antimonial drugs","volume":"7","author":"Frezard","year":"2010","journal-title":"Expert Opin. Drug Delivery"},{"key":"10.1016\/j.ejpb.2015.04.018_b0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopha.2005.06.011","article-title":"Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations","volume":"59","author":"Papagiannaros","year":"2005","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2015.04.018_b0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/dkm396","article-title":"Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine","volume":"61","author":"Banerjee","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2015.04.018_b0090","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.2392684","article-title":"Inhibition of leishmanias but not host macrophages by the antitubulin herbicide trifluralin","volume":"249","author":"Chan","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2015.04.018_b0095","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.90.12.5657","article-title":"Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans","volume":"90","author":"Chan","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.04.018_b0100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejpb.2008.08.001","article-title":"Trifluralin liposomal formulations active against Leishmania donovani infections","volume":"71","author":"Carvalheiro","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.04.018_b0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tvjl.2007.07.016","article-title":"Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis","volume":"178","author":"Marques","year":"2008","journal-title":"Vet. J."},{"key":"10.1016\/j.ejpb.2015.04.018_b0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejpb.2012.06.013","article-title":"Formulation of ORZ liposomes: in vitro studies and in vivo fate","volume":"82","author":"Lopes","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.04.018_b0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejps.2011.09.017","article-title":"Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis","volume":"45","author":"Lopes","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.04.018_b0120","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1166\/jbn.2014.1874","article-title":"Liposomes versus lipid nanoparticles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis","volume":"10","author":"Lopes","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.04.018_b0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bmc.2009.10.059","article-title":"Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents","volume":"18","author":"Esteves","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.04.018_b0130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/BF02531316","article-title":"Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots","volume":"5","author":"Rouser","year":"1970","journal-title":"Lipids"},{"key":"10.1016\/j.ejpb.2015.04.018_b0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0001-706X(93)90083-N","article-title":"A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites","volume":"55","author":"Huber","year":"1993","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejpb.2015.04.018_b0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.imbio.2008.07.001","article-title":"Identification of regulatory T cells during experimental Leishmania infantum infection","volume":"214","author":"Rodrigues","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.ejpb.2015.04.018_b0145","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1124\/mol.64.6.1325","article-title":"Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4, N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites","volume":"64","author":"Werbovetz","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.04.018_b0150","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1021\/jm0304461","article-title":"Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against african trypanosomes and Leishmania","volume":"47","author":"Bhattacharya","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.04.018_b0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1584\/jpestics.G06-50","article-title":"Synthesis and herbicidal activity of a pentafluorosulfanyl analog of trifluralin","volume":"32","author":"Lim","year":"2007","journal-title":"J. Pestic. Sci."},{"key":"10.1016\/j.ejpb.2015.04.018_b0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2015.04.018_b0165","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/08982109309150726","article-title":"Amphotericin B formulated in liposomes and lipid based systems: a review","volume":"3","author":"Szoka","year":"1993","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejpb.2015.04.018_b0170","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1128\/AAC.47.12.3774-3779.2003","article-title":"Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B","volume":"47","author":"Larabi","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2015.04.018_b0175","series-title":"Liposomes a pratical approach","first-page":"149","article-title":"Stability, storage, and sterilization of liposomes","author":"Zuidam","year":"2003"},{"key":"10.1016\/j.ejpb.2015.04.018_b0180","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1021\/jm701166b","article-title":"Design and synthesis of potent antileishmanial cycloalkylidene-substituted ether phospholipid derivatives","volume":"51","author":"Calogeropoulou","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.04.018_b0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpharm.2009.08.034","article-title":"Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice","volume":"383","author":"Mirahmadi","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.04.018_b0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00204-009-0485-0","article-title":"Genotoxic effects of the antileishmanial drug glucantime","volume":"84","author":"Lima","year":"2010","journal-title":"Arch. Toxicol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T13:31:43Z","timestamp":1566653503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115001988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":38,"alternative-id":["S0939641115001988"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.04.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}